A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies
- Conditions
- Cancer, Tumors, Carcinoma
- Registration Number
- JPRN-jRCT2080220530
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Ages Eligible for Study: 20 Years to 75 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Inclusion Criteria:
-Patients diagnosed with solid tumour but which have no standard treatment or did not respond to previous treatments.
-Patients who usually have mild symptoms capable of walking and light and sedentary work.
-Patients who can stay in hospital at least during 4 weeks.
-Patients who have received treatment with anti-cancer agent within 4 weeks prior to first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.
-Patients with abnormally low levels of neutrophil count, platelet count, or haemoglobin, indicators of bone marrow function.
-Patients who received therapeutic radiotherapy at central nervous system within 3 months prior to first dose of study treatment; the other sites within 4 weeks; or local site within 2 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies
- Secondary Outcome Measures
Name Time Method